• TearClear announced the company’s lead product, TC-002 (latanoprost ophthalmic solution 0.005%), met the primary and all secondary endpoints in the CLEAR Phase 3 pivotal trial that evaluated the efficacy and safety of TC-002 in patients with elevated IOP. The primary efficacy endpoint was the difference in mean change from baseline in IOP at weeks 2, 6 and 12 at 8 a.m., 10 a.m. and 4 p.m., and the secondary efficacy endpoints included diurnal (average of 8 a.m., 10 a.m. and 4 p.m. measurements) IOP at weeks 2, 6 and 12. With these results, TearClear plans to file a new drug application with the FDA in the first quarter of 2023. Upon approval, TC-002 will offer patients the first and only means of delivering preservative-free doses of latanoprost from conventional multi-dose bottles.

• Haag-Streit will host a variety of educational webinars as part of its Biometry Focus Month in November. This series of webinars will be delivered by notable key opinion leaders and  complemented by Haag-Streit biometry product specialists. Hosted on Zoom, across multiple time-zones (CET, EDT and EST), these webinars are aimed at cataract and refractive surgeons, as well as myopia specialists, and will cover both clinical and practical aspects of using the Eyestar 900, Lenstar 900 and Lenstar Myopia devices. For the detailed program, and to register for any webinar, visit www.haag-streit.com/biometryfocusmonth.

• PatientPoint announced the acquisition of Rendia, the provider of point-of-care content for eye-care providers sold on a subscription basis. With PatientPoint's expansion into ophthalmology and optometry, PatientPoint's tech-enabled point-of-care network now engages health-care providers and patients across 20 medical specialties. Through the acquisition, PatientPoint will net Rendia's technology platform, provider portal and content library. As part of the transaction Rendia's name will be retained, and the company will be referred to as Rendia, a PatientPoint company.

Quick Notes is published weekly. Unless otherwise noted, the information presented is based on press releases. Find earlier editions here. To submit a press release to be considered for publication, click here.